1008530-98-0Relevant academic research and scientific papers
HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS
-
Page/Page column 55-56, (2008/06/13)
This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.
MATRIX METALLOPROTEASE INHIBITORS
-
Page/Page column 48-49, (2010/11/30)
The present invention relates to compounds of Formula I, wherein R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. In addition, the present invention relates to methods treating disorders related to matrix metalloproteases. More particularl
β-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: Part 2. Optimization of α-amino substituents
Yang, Shyh-Ming,Scannevin, Robert H.,Wang, Bingbing,Burke, Sharon L.,Huang, Zhihong,Karnachi, Prabha,Wilson, Lawrence J.,Rhodes, Kenneth J.,Lagu, Bharat,Murray, William V.
, p. 1140 - 1145 (2008/09/19)
The introduction and the optimization of an α-amino substituent based on a series of α-hydroxy-β-N-biaryl ether sulfonamide hydroxamates is described. The modification leads to a new series of MMP-2/MMP-9 inhibitors with enhanced inhibitory activities and
β-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: Part 1. Design, synthesis, and lead identification
Yang, Shyh-Ming,Scannevin, Robert H.,Wang, Bingbing,Burke, Sharon L.,Wilson, Lawrence J.,Karnachi, Prabha,Rhodes, Kenneth J.,Lagu, Bharat,Murray, William V.
, p. 1135 - 1139 (2008/12/22)
A new series of β-N-biaryl ether sulfonamide hydroxamates as novel gelatinase inhibitors is described. These compounds exhibit good potency for MMP-2 and MMP-9 without inhibiting MMP-1. The structure-activity relationships (SAR) reveal the biaryl ether ty
